therapeutic advances in neurological disorders | December 18, 2019
Milà-Alomà M, Suárez-Calvet M and Molinuevo JL. Therapeutic Advances in Neurological Disorders. 2019;12:1756286419888819. doi: https://doi.org/10.1177/1756286419888819 ABSTRACT
June 04, 2019
Quanterix is re-engineering ultrasensitivity with the launch of the Simoa HD-X Analyzer™, the latest model fully automated Simoa bead-based immunoassay platform.
The Quanterix SR-X is the latest instrument powered by Simoa® technology offering researchers access to ultra-sensitive biomarker detection capabilities in a compact affordable system.
The Simoa p24 Antigen Assay is an ultra-sensitive digital immunoassay providing 1,000 times improvement in detection limits compared with a traditional ELISA. The method can be used to detect early reactivation of infectious virus from latent reservoirs and determine efficacy of drugs and therap
The Quanterix SP-X Imaging and Analysis System is the first complete benchtop system offering true multiplex detection capabilities at both acute and baseline levels.
Blood Will Tell
The ability to detect neurological biomarkers at ultra-low levels, which have traditionally only been detectable in cerebrospinal fluid, will transform the way brain injuries and diseases are diagnosed. Learn more about how the Simoa Platform can advance your CNS biomarker detection!
The Quanterix Accelerator Laboratory is a dedicated laboratory environment for digitized biomarker research, custom assay development, and clinical sample testing using our Simoa™ technology.
The Simoa HD-1 Analyzer™ is a fully automated instrument for running immunoassays using Quanterix’ proprietary single molecule array, or Simoa, platform.
Simoa assays are designed for the HD-1/HD-X Analyzer, the SR-X Ultra-Sensitive Biomarker Detection System and the SP-X Imaging and Analysis System to provide researchers ultra-sensitive analysis of protein concentration with the high precision and performance required to meet the needs of discov